|
시장보고서
상품코드
1542674
세계의 크리티컬 케어 치료학 시장Critical Care Therapeutics |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
세계의 크리티컬 케어 치료학 시장은 2030년까지 74억 달러에 달할 전망
2023년에 50억 달러로 추정되는 세계의 크리티컬 케어 치료학 시장은 2023-2030년의 분석 기간에 CAGR 5.6%로 성장하며, 2030년에는 74억 달러에 달할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 알부민 약제 클래스는 CAGR 6.9%를 기록하며, 분석 기간 종료시에는 37억 달러에 달할 것으로 예측됩니다. 프로트롬빈 복합체 농축 약제 클래스 부문의 성장률은 분석 기간 중 CAGR 4.6%로 추정됩니다.
미국 시장은 13억 달러, 중국은 CAGR 9.0%로 성장할 것으로 예측
미국의 크리티컬 케어 치료학 시장은 2023년에 13억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 18억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2023-2030년 CAGR은 9.0%입니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.1%와 4.4%로 예측됩니다. 유럽에서는 독일이 CAGR 4.0%로 성장할 것으로 예측됩니다.
세계의 크리티컬 케어 치료학 시장 - 주요 동향과 촉진요인 정리
생존의 위기: 크리티컬 케어 치료학은 중환자 치료에 어떤 혁명을 가져올 것인가?
크리티컬 케어 치료학은 중환자실(ICU)에서 생명을 위협하는 건강 상태에 직면한 환자를 위해 특별히 고안된 다양한 치료법을 포괄합니다. 이러한 치료법에는 다발성 장기 부전으로 이어질 수 있는 급성 질환을 관리하기 위해 첨단 약리학적 개입, 혈액 제제, 조정된 생명 유지 수단이 포함됩니다. 주요 목표는 생명 기능을 안정시키고 회복이 가능할 때까지 더 이상의 악화를 막는 것입니다. 이러한 치료제는 패혈증, 급성 호흡곤란 증후군(ARDS), 심부전 및 기타 심각한 상태를 관리하는 데 필수적입니다. 혈관확장제, 항응고제, 항생제, 코르티코스테로이드 및 기타 약물을 사용하여 심각한 스트레스를 받고 있는 장기 시스템을 지원하는 경우가 많습니다.
크리티컬 케어 치료학 분야는 어떤 혁신으로 형성되고 있는가?
중환자실과 같은 열악한 환경에서 환자의 예후를 개선하는 데 있으며, 중환자 치료의 혁신은 매우 중요합니다. 최근 몇년사이에는 부작용이 적고 효능이 더 높은 보다 표적화된 약물 요법의 개발이 이루어지고 있습니다. 예를 들어 정밀의학 접근법(Precision Medicine Approach)의 도입으로 개별 유전자 프로파일에 기반한 치료가 가능해져 중증 환자의 치료 결과를 개선할 수 있습니다. 또한 패혈증과 같은 질환을 치료하기 위해 모노클로널 항체나 재조합 단백질과 같은 생물학적 제제를 사용하는 것은 단순히 증상을 관리하는 것이 아니라 중증 질환의 근본적인 원인을 치료할 수 있는 새로운 길을 열어주었습니다. 이러한 기술 혁신은 중증 질환의 병태생리에 대한 지속적인 연구로 지원되고 있으며, 치료 최적화를 위한 지속적인 개선 기반을 제공합니다.
중환자 치료의 효과에 영향을 미치는 과제는?
큰 진전에도 불구하고 몇 가지 문제가 중환자 치료의 효과에 영향을 미치고 있습니다. 치료에 대한 환자의 반응은 매우 다양하므로 중증 환자 관리가 복잡해지고 표준화된 치료 프로토콜이 효과적이지 않을 수 있습니다. 또한 중환자실은 질병의 빠른 진행과 높은 합병증 위험과 같은 독특한 과제를 안고 있으며, 매우 역동적이고 즉각적인 치료 전략이 필요합니다. 또한 항균제 내성 위험은 특히 광범위 항생제를 자주 사용하는 환경에서 감염을 효과적으로 치료하는 데 심각한 위협이 되고 있습니다. 이러한 문제를 해결하기 위해서는 최신 임상적 증거와 치료 기술에 기반한 다학제적 접근과 치료 프로토콜의 지속적인 적응이 필요합니다.
크리티컬 케어 치료학 시장의 성장을 가속하는 주요 요인은 무엇인가?
중환자 치료 시장의 성장은 중환자 치료의 복잡하고 긴급한 요구를 반영하는 몇 가지 요인에 의해 주도되고 있습니다. 인구 고령화로 인한 세계 헬스케어 수요 증가와 중증 질환으로 이어지는 만성질환의 유병률 증가는 중요한 성장 동인이며, COVID-19 팬데믹과 같은 최근 세계 보건 사건은 효과적인 중환자 치료제에 대한 수요를 크게 증가시켜 중증 급성 질환에 대응할 수 있는 강력한 의료 시스템의 필요성을 강조하고 있습니다.에 대응할 수 있는 탄탄한 의료 시스템의 필요성을 강조하고 있습니다. 신약 발견과 치료법 개발로 이어지는 의학 연구의 발전도 시장 확대에 기여하고 있습니다. 또한 특히 신흥 경제권에서 전 세계 의료비 지출이 증가하면서 중환자실내 첨단 치료 솔루션의 채택이 증가하고 있습니다. 이러한 요인들이 종합적으로 중환자 치료 분야의 지속적인 발전과 확장을 촉진하고 세계 의료 인프라에서 중환자 치료 분야의 중요한 역할을 강조하고 있습니다.
조사 대상 기업의 예(총 37건)
- Abeona Therapeutics Inc.
- ADMA Biologics, Inc.
- Albumedix Ltd.
- Asklepios Biopharmaceutical, Inc.
- Aspen Pharmacare Holdings Ltd.
- Baxter International Inc.
- Bayer Healthcare AG
- Bio Products Laboratory Ltd.
- BioDelivery Sciences International, Inc.
- Biogen, Inc.
- BioMarin Pharmaceutical Inc.
- Biotest Pharmaceuticals Corporation
- Bristol-Myers Squibb Company
- Catalyst Biosciences, Inc.
- China Biologic Products Holdings, Inc.
- Cosmo Pharmaceuticals NV
- CSL Behring
- Grifols International SA
- Kamada Ltd.
- Kedrion Biopharma, Inc.
- Medxbio Pte. Ltd.
- Merck & Co., Inc.
- Mitsubishi Tanabe Pharma Corporation
- Novo Nordisk A/S
- Novozymes A/S
- Octapharma AG
- Portola Pharmaceuticals, Inc.
- ProMetic Life Sciences, Inc.
- rEVO Biologics, Inc.
- Rockwell Medical
- Sanquin
- Shanghai RAAS Blood Products Co., Ltd.
- Shire PLC
- Teva Pharmaceutical Industries Ltd.
- The Medicines Company
- Thermo Fisher Scientific, Inc.
- Ventria Bioscience
목차
제1장 조사 방법
제2장 개요
- 시장 개요
- 주요 기업
- 시장 동향과 촉진요인
- 세계 시장의 전망
제3장 시장 분석
- 미국
- 캐나다
- 일본
- 중국
- 유럽
- 프랑스
- 독일
- 이탈리아
- 영국
- 스페인
- 러시아
- 기타 유럽
- 아시아태평양
- 호주
- 인도
- 한국
- 기타 아시아태평양
- 라틴아메리카
- 아르헨티나
- 브라질
- 멕시코
- 기타 라틴아메리카
- 중동
- 이란
- 이스라엘
- 사우디아라비아
- 아랍에미리트
- 기타 중동
- 아프리카
제4장 경쟁
KSA 24.09.03Global Critical Care Therapeutics Market to Reach US$7.4 Billion by 2030
The global market for Critical Care Therapeutics estimated at US$5.0 Billion in the year 2023, is expected to reach US$7.4 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2023-2030. Albumin Drug Class, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$3.7 Billion by the end of the analysis period. Growth in the Prothrombin Complex Concentrates Drug Class segment is estimated at 4.6% CAGR over the analysis period.
The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 9.0% CAGR
The Critical Care Therapeutics market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 9.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 4.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.
Global Critical Care Therapeutics Market - Key Trends and Drivers Summarized
At the Edge of Survival: How Are Critical Care Therapeutics Revolutionizing Intensive Care?
Critical care therapeutics encompass a range of medical treatments specifically designed for patients in intensive care units (ICUs) who are facing life-threatening health conditions. These treatments include advanced pharmacological interventions, blood products, and life-support measures tailored to manage acute illnesses that can lead to multiple organ failure. The primary goal is to stabilize vital functions and prevent further deterioration until recovery becomes feasible. These therapeutics are integral in the management of sepsis, acute respiratory distress syndrome (ARDS), cardiac failures, and other critical conditions. They often involve the use of vasoactive drugs, anticoagulants, antibiotics, corticosteroids, and other agents that support organ systems under severe stress.
What Innovations Are Shaping the Field of Critical Care Therapeutics?
Innovation in critical care therapeutics is crucial in improving patient outcomes in environments as challenging as the ICU. Recent advancements include the development of more targeted drug therapies that offer higher efficacy with fewer side effects. For instance, the introduction of precision medicine approaches allows for treatments based on individual genetic profiles, potentially enhancing the therapeutic outcomes for critically ill patients. Additionally, the use of biologics—such as monoclonal antibodies and recombinant proteins—to treat conditions like sepsis has opened new avenues for addressing the underlying causes of critical illnesses rather than just managing symptoms. These innovations are supported by ongoing research into the pathophysiology of critical conditions, providing a continuously improving basis for therapy optimization.
What Challenges Impact the Efficacy of Critical Care Therapeutics?
Despite significant advancements, several challenges impact the efficacy of critical care therapeutics. The high variability in patient responses to treatments can complicate the management of critical illnesses, making standardized treatment protocols less effective. The critical care environment also presents unique challenges, such as the rapid progression of diseases and the high risk of complications, which require exceptionally dynamic and responsive treatment strategies. Moreover, the risk of antimicrobial resistance, particularly in settings where broad-spectrum antibiotics are frequently used, poses a serious threat to treating infections effectively. Addressing these challenges requires a multidisciplinary approach and continuous adaptation of treatment protocols based on the latest clinical evidence and therapeutic technologies.
What Are the Key Drivers Propelling the Growth of the Critical Care Therapeutics Market?
The growth in the critical care therapeutics market is driven by several factors, reflecting the complex and urgent nature of critical care needs. Increasing global healthcare demands due to a rising aging population and higher prevalence of chronic diseases that can lead to critical illness are significant growth drivers. The recent global health events, such as the COVID-19 pandemic, have also dramatically increased the demand for effective critical care therapeutics, highlighting the need for robust health systems capable of managing severe acute conditions. Advances in medical research that lead to new drug discoveries and therapeutic approaches contribute to market expansion as well. Furthermore, increased healthcare spending worldwide, especially in emerging economies, supports the adoption of advanced therapeutic solutions in ICUs. These factors collectively fuel the ongoing development and expansion of the critical care therapeutics sector, underscoring its vital role in global health infrastructure.
Select Competitors (Total 37 Featured) -
- Abeona Therapeutics Inc.
- ADMA Biologics, Inc.
- Albumedix Ltd.
- Asklepios Biopharmaceutical, Inc.
- Aspen Pharmacare Holdings Ltd.
- Baxter International Inc.
- Bayer Healthcare AG
- Bio Products Laboratory Ltd.
- BioDelivery Sciences International, Inc.
- Biogen, Inc.
- BioMarin Pharmaceutical Inc.
- Biotest Pharmaceuticals Corporation
- Bristol-Myers Squibb Company
- Catalyst Biosciences, Inc.
- China Biologic Products Holdings, Inc.
- Cosmo Pharmaceuticals NV
- CSL Behring
- Grifols International SA
- Kamada Ltd.
- Kedrion Biopharma, Inc.
- Medxbio Pte. Ltd.
- Merck & Co., Inc.
- Mitsubishi Tanabe Pharma Corporation
- Novo Nordisk A/S
- Novozymes A/S
- Octapharma AG
- Portola Pharmaceuticals, Inc.
- ProMetic Life Sciences, Inc.
- rEVO Biologics, Inc.
- Rockwell Medical
- Sanquin
- Shanghai RAAS Blood Products Co., Ltd.
- Shire PLC
- Teva Pharmaceutical Industries Ltd.
- The Medicines Company
- Thermo Fisher Scientific, Inc.
- Ventria Bioscience
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Critical Care Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
- Global Economic Update
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Global Incidence of Chronic Diseases Drives Demand for Critical Care Therapeutics
- Advancements in Biotechnology Propel Development of Innovative Critical Care Drugs
- Increased Investment in Healthcare Infrastructure Supports Critical Care Therapeutic Availability
- Growing Geriatric Population Bolsters Market for Age-Specific Therapeutic Solutions
- Rise in Healthcare Expenditure Worldwide Sustains Growth in Therapeutic Development
- Demand for Multifunctional Drugs Amplifies Development of Combination Therapies
- Technological Advances in Drug Delivery Systems Enhance Critical Care Management
- Health Insurance Coverage Influence Therapeutic Adoption
- Expansion of Emergency Care Units Worldwide Drives Need for Advanced Therapeutics
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Critical Care Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 2: World Historic Review for Critical Care Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 3: World 16-Year Perspective for Critical Care Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for Albumin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 5: World Historic Review for Albumin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 6: World 16-Year Perspective for Albumin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 7: World Recent Past, Current & Future Analysis for Prothrombin Complex Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 8: World Historic Review for Prothrombin Complex Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 9: World 16-Year Perspective for Prothrombin Complex Concentrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 10: World Recent Past, Current & Future Analysis for Antithrombin Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 11: World Historic Review for Antithrombin Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 12: World 16-Year Perspective for Antithrombin Concentrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 13: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 14: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 15: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 16: World Recent Past, Current & Future Analysis for Deep Vein Thrombosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 17: World Historic Review for Deep Vein Thrombosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 18: World 16-Year Perspective for Deep Vein Thrombosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 19: World Recent Past, Current & Future Analysis for Pulmonary Embolism (PE) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 20: World Historic Review for Pulmonary Embolism (PE) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 21: World 16-Year Perspective for Pulmonary Embolism (PE) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 22: World Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 23: World Historic Review for Acute Coronary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 24: World 16-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 25: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 26: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 27: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 28: World Critical Care Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
- UNITED STATES
- Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- TABLE 29: USA Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 30: USA Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 31: USA 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 32: USA Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 33: USA Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 34: USA 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- CANADA
- TABLE 35: Canada Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 36: Canada Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 37: Canada 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 38: Canada Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 39: Canada Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 40: Canada 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- JAPAN
- Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- TABLE 41: Japan Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 42: Japan Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 43: Japan 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 44: Japan Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 45: Japan Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 46: Japan 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- CHINA
- Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- TABLE 47: China Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 48: China Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 49: China 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 50: China Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 51: China Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 52: China 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- EUROPE
- Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- TABLE 53: Europe Recent Past, Current & Future Analysis for Critical Care Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 54: Europe Historic Review for Critical Care Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 55: Europe 16-Year Perspective for Critical Care Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
- TABLE 56: Europe Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 57: Europe Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 58: Europe 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 59: Europe Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 60: Europe Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 61: Europe 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- FRANCE
- Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- TABLE 62: France Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 63: France Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 64: France 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 65: France Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 66: France Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 67: France 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- GERMANY
- Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- TABLE 68: Germany Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 69: Germany Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 70: Germany 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 71: Germany Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 72: Germany Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 73: Germany 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- ITALY
- TABLE 74: Italy Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 75: Italy Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 76: Italy 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 77: Italy Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 78: Italy Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 79: Italy 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- UNITED KINGDOM
- Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- TABLE 80: UK Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 81: UK Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 82: UK 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 83: UK Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 84: UK Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 85: UK 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- SPAIN
- TABLE 86: Spain Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 87: Spain Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 88: Spain 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 89: Spain Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 90: Spain Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 91: Spain 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- RUSSIA
- TABLE 92: Russia Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 93: Russia Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 94: Russia 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 95: Russia Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 96: Russia Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 97: Russia 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- REST OF EUROPE
- TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 99: Rest of Europe Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 100: Rest of Europe 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 102: Rest of Europe Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 103: Rest of Europe 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- ASIA-PACIFIC
- Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Critical Care Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 105: Asia-Pacific Historic Review for Critical Care Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 106: Asia-Pacific 16-Year Perspective for Critical Care Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
- TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 108: Asia-Pacific Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 109: Asia-Pacific 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 111: Asia-Pacific Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 112: Asia-Pacific 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- AUSTRALIA
- Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
- TABLE 113: Australia Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 114: Australia Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 115: Australia 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 116: Australia Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 117: Australia Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 118: Australia 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- INDIA
- Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
- TABLE 119: India Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 120: India Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 121: India 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 122: India Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 123: India Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 124: India 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- SOUTH KOREA
- TABLE 125: South Korea Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 126: South Korea Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 127: South Korea 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 128: South Korea Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 129: South Korea Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 130: South Korea 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- REST OF ASIA-PACIFIC
- TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 132: Rest of Asia-Pacific Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 135: Rest of Asia-Pacific Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- LATIN AMERICA
- Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
- TABLE 137: Latin America Recent Past, Current & Future Analysis for Critical Care Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 138: Latin America Historic Review for Critical Care Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 139: Latin America 16-Year Perspective for Critical Care Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
- TABLE 140: Latin America Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 141: Latin America Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 142: Latin America 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 143: Latin America Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 144: Latin America Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 145: Latin America 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- ARGENTINA
- TABLE 146: Argentina Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 147: Argentina Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 148: Argentina 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 149: Argentina Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 150: Argentina Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 151: Argentina 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- BRAZIL
- TABLE 152: Brazil Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 153: Brazil Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 154: Brazil 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 155: Brazil Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 156: Brazil Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 157: Brazil 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- MEXICO
- TABLE 158: Mexico Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 159: Mexico Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 160: Mexico 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 161: Mexico Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 162: Mexico Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 163: Mexico 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- REST OF LATIN AMERICA
- TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 165: Rest of Latin America Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 166: Rest of Latin America 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 168: Rest of Latin America Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 169: Rest of Latin America 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- MIDDLE EAST
- Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
- TABLE 170: Middle East Recent Past, Current & Future Analysis for Critical Care Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 171: Middle East Historic Review for Critical Care Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 172: Middle East 16-Year Perspective for Critical Care Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
- TABLE 173: Middle East Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 174: Middle East Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 175: Middle East 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 176: Middle East Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 177: Middle East Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 178: Middle East 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- IRAN
- TABLE 179: Iran Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 180: Iran Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 181: Iran 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 182: Iran Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 183: Iran Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 184: Iran 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- ISRAEL
- TABLE 185: Israel Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 186: Israel Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 187: Israel 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 188: Israel Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 189: Israel Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 190: Israel 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- SAUDI ARABIA
- TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 192: Saudi Arabia Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 193: Saudi Arabia 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 195: Saudi Arabia Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 196: Saudi Arabia 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- UNITED ARAB EMIRATES
- TABLE 197: UAE Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 198: UAE Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 199: UAE 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 200: UAE Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 201: UAE Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 202: UAE 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- REST OF MIDDLE EAST
- TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 204: Rest of Middle East Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 205: Rest of Middle East 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 207: Rest of Middle East Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 208: Rest of Middle East 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
- AFRICA
- Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
- TABLE 209: Africa Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 210: Africa Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 211: Africa 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 212: Africa Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 213: Africa Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 214: Africa 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
IV. COMPETITION
비교리스트